.jpeg)
2026-09-28 04:44:36
Elagolix is an oral GnRH receptor antagonist that lowers LH/FSH and ovarian estrogen for moderate-to-severe endometriosis pain, including dysmenorrhea, non-menstrual pelvic pain, and dyspareunia. It is not a conventional analgesic and not an oncology targeted drug; use 150mg once daily or 200mg twice daily with bone-density, mood, liver, and pregnancy monitoring.
2026-09-08 06:24:42
Fezolinetant is a non-hormonal oral medication for moderate to severe vasomotor symptoms of menopause. This article details standard dosing, missed dose management, and liver function monitoring.
2026-08-28 07:03:42
Elagolix (brand name Orilissa) is FDA-approved for moderate to severe pain caused by endometriosis, including painful periods. This article explains its mechanism, who should use it, and safety limits.
2026-07-29 06:19:15
Elagolix is an oral GnRH receptor antagonist used to treat endometriosis-associated pain. This article reviews its common side effects, bone density impact, emotional changes, and safety considerations to help patients understand the medication comprehensively.
2026-06-26 04:06:33
Fezolinetant is an NK3 receptor antagonist primarily used to treat menopausal hot flashes. This article provides an in-depth analysis of its relationship with depression, including current research evidence, indirect mood benefits from hot flash improvement, and clinical prescribing recommendations to help patients correctly understand the drug's scope of use.
2026-06-26 03:49:45
Fezolinetant is a novel NK3 receptor antagonist used to treat moderate to severe vasomotor symptoms (hot flashes) associated with menopause. This article provides a detailed overview of the incidence, clinical presentation, and management strategies for its common side effects, helping patients use the medication safely and effectively manage discomfort.
2026-05-20 04:57:13
A comprehensive guide to Niraparib (Zejula), a once-daily PARP inhibitor for maintaining remission in ovarian, fallopian tube, and peritoneal cancers. Learn about HRD selection, dosing by weight, and critical blood monitoring.
